Mission Wealth Management LP boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 99.6% in the first quarter, HoldingsChannel.com reports. The fund owned 25,618 shares of the company’s stock after purchasing an additional 12,784 shares during the period. Mission Wealth Management LP’s holdings in Neurocrine Biosciences were worth $2,257,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. SG Americas Securities LLC raised its position in Neurocrine Biosciences by 6.8% during the first quarter. SG Americas Securities LLC now owns 2,106 shares of the company’s stock worth $186,000 after acquiring an additional 135 shares during the period. JGP Global Gestao de Recursos Ltda. raised its position in Neurocrine Biosciences by 9.4% during the first quarter. JGP Global Gestao de Recursos Ltda. now owns 3,278 shares of the company’s stock worth $289,000 after acquiring an additional 281 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Neurocrine Biosciences by 6.4% in the first quarter. Nisa Investment Advisors LLC now owns 5,965 shares of the company’s stock valued at $526,000 after buying an additional 358 shares during the last quarter. Steinberg Global Asset Management raised its position in shares of Neurocrine Biosciences by 2.7% in the first quarter. Steinberg Global Asset Management now owns 15,923 shares of the company’s stock valued at $1,403,000 after buying an additional 412 shares during the last quarter. Finally, Chartwell Investment Partners LLC raised its position in shares of Neurocrine Biosciences by 5.4% in the first quarter. Chartwell Investment Partners LLC now owns 8,107 shares of the company’s stock valued at $714,000 after buying an additional 413 shares during the last quarter. Institutional investors own 96.14% of the company’s stock.

Shares of NBIX traded down $0.08 during mid-day trading on Friday, reaching $84.00. The stock had a trading volume of 11,367 shares, compared to its average volume of 644,266. The company has a current ratio of 8.79, a quick ratio of 8.61 and a debt-to-equity ratio of 0.96. Neurocrine Biosciences, Inc. has a 52-week low of $64.72 and a 52-week high of $126.98. The firm has a market capitalization of $7.68 billion, a P/E ratio of 382.41 and a beta of 1.46.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Monday, April 29th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.07). Neurocrine Biosciences had a negative net margin of 7.56% and a negative return on equity of 9.14%. The firm had revenue of $138.40 million during the quarter, compared to analysts’ expectations of $136.77 million. During the same period in the prior year, the company posted ($0.47) EPS. The company’s revenue for the quarter was up 94.7% compared to the same quarter last year. Equities research analysts predict that Neurocrine Biosciences, Inc. will post -0.08 earnings per share for the current fiscal year.

In related news, insider Haig P. Bozigian sold 17,486 shares of the company’s stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $80.03, for a total value of $1,399,404.58. Following the completion of the sale, the insider now owns 159,462 shares of the company’s stock, valued at $12,761,743.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Haig P. Bozigian sold 1,300 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $80.03, for a total transaction of $104,039.00. Following the completion of the sale, the insider now directly owns 143,276 shares of the company’s stock, valued at approximately $11,466,378.28. The disclosure for this sale can be found here. Insiders sold 142,732 shares of company stock valued at $11,388,472 in the last three months. 4.30% of the stock is currently owned by insiders.

NBIX has been the subject of a number of recent research reports. Barclays reiterated a “buy” rating and issued a $110.00 target price on shares of Neurocrine Biosciences in a research report on Friday, March 29th. ValuEngine upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Tuesday, March 19th. Zacks Investment Research upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating and set a $90.00 target price for the company in a research report on Wednesday, April 24th. BidaskClub upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, March 14th. Finally, Guggenheim initiated coverage on shares of Neurocrine Biosciences in a research report on Tuesday, June 4th. They issued a “neutral” rating and a $88.00 target price for the company. Six research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Neurocrine Biosciences presently has an average rating of “Buy” and an average target price of $102.16.

TRADEMARK VIOLATION NOTICE: “Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Mission Wealth Management LP” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/neurocrine-biosciences-inc-nasdaqnbix-shares-bought-by-mission-wealth-management-lp/3041623.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Further Reading: Determine Your Level of Risk Tolerance

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.